SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001047469-19-001846
Filing Date
2019-04-01
Accepted
2019-04-01 17:20:23
Documents
7
Period of Report
2019-05-23
Effectiveness Date
2019-04-01

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2238305zdef14a.htm DEF 14A 309583
2 G353336.JPG g353336.jpg GRAPHIC 21698
3 G885637.JPG g885637.jpg GRAPHIC 8309
4 G900167.JPG g900167.jpg GRAPHIC 8323
5 G816472.JPG g816472.jpg GRAPHIC 15772
6 G72322BCI001.JPG g72322bci001.jpg GRAPHIC 114431
7 G72322BEI001.GIF g72322bei001.gif GRAPHIC 71783
  Complete submission text file 0001047469-19-001846.txt   642344
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38410 | Film No.: 19721884
SIC: 2834 Pharmaceutical Preparations